Resources Repository
-
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Value of Information | Business/Industry | Economics/Finance | Policy/Regulation | Child/Nutrition | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Operations Research | Infectious Diseases | Maternal/Reproductive Health | Chronic Disease/Risk | Health Systems | Health/Medicine | Science/Technology | Global -
ReviewPublication 2011Simulation Models of Obesity: A Review of the Literature
Simulation models combine information from a variety of sources to provide a useful tool for …
Simulation models combine information from a variety of sources to provide a useful tool for examining how the effects of obesity unfold over time and impact population health. They can aid in the understanding of the complex interaction of the drivers of diet and activity and their relation to health outcomes. This paper provided an overview of different types of simulation models used to evaluate the potential impact of policies to address the obesity epidemic.…
Calibration/Validation | State-Transition | Food/Agriculture | Economics/Finance | Child/Nutrition | Mathematical Models | Microsimulation | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine -
BookPublication 1980Clinical Decision Analysis
This text was conceived and developed in the Harvard T.H. Chan School of Public Health …
This text was conceived and developed in the Harvard T.H. Chan School of Public Health at the Center for the Analysis of Health Practices. The book had its origins in a set of classroom materials developed during the academic year 1974-75 for an elective course in medical decision making at the Harvard Medical School. In this book students are shown how to structure clinical decision problems, how to systematically formulate the intertwining roles of diagnosis and treatment, how to…
Probability/Bayes | Test Performance | State-Transition | Value of Information | Economics/Finance | Child/Nutrition | Preferences/Values | Costing Methods | Health Outcomes | Decision Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health/Medicine | Global | North America | Europe | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
BookPublication 2013Making Hard Decisions with Decision Tools, 3rd Edition
Making Hard Decisions with Decision Tools® is a new edition and teaches the fundamental ideas …
Making Hard Decisions with Decision Tools® is a new edition and teaches the fundamental ideas of decision analysis, without an overly technical explanation of the mathematics used in decision analysis. This new version has been purposefully written to be more relevant to students in business and engineering compared to previous versions. This new version also incorporates and implements the powerful DecisionTools® software by Palisade Corporation. At the end of each chapter, topics are illustrated with step-by-step instructions…
Probability/Bayes | Test Performance | Value of Information | Business/Industry | Policy/Regulation | Preferences/Values | Microsimulation | Decision Analysis | Energy/Engineering | Health/Medicine | Military/Defense | Science/Technology | Global | North America | Europe -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
State-Transition | Business/Industry | Economics/Finance | Policy/Regulation | Mathematical Models | Benefit-Cost Analysis | Infectious Diseases | Government/Law | Health/Medicine | North America -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
State-Transition | Value of Information | Economics/Finance | Policy/Regulation | Benefit-Cost Analysis | Infectious Diseases | North America | Europe -
ArticlePublication 2017Modeled Health Benefits of a SSB Tax across Different Socioeconomic Groups in Australia
This analysis assessed the potential cost-effectiveness, health gains, and financial impacts of a 20% sugar-sweetened …
This analysis assessed the potential cost-effectiveness, health gains, and financial impacts of a 20% sugar-sweetened beverage (SSB) tax for Australia. Australia-specific price elasticities were used to predict decreases in SSB consumption for each socio-economic quintile. Changes in body mass index (BMI) were based on SSB consumption, BMI from the Australian Health Survey, and energy balance equations. Markov cohort models were used to estimate the health-adjusted life years (HALYs) gained, healthcare costs saved, and out-of-pocket costs…
State-Transition | Food/Agriculture | Economics/Finance | Policy/Regulation | Mathematical Models | Chronic Disease/Risk | Government/Law | Health/Medicine | Oceania -
Resource PackWeb Portal, Teaching Resource 2017Resource Pack: Valuing Vaccines and GAVI
This resource pack on valuing vaccines and GAVI was curated by the Center for Health …
This resource pack on valuing vaccines and GAVI was curated by the Center for Health Decision Science to showcase existing information and analyses to motivate students, educators and others to pursue new applications of decision science methods to the public health challenge of vaccine preventable illnesses.
Calibration/Validation | Dynamic Transmission | Economics/Finance | Child/Nutrition | Preferences/Values | Priority Setting/Ethics | Costing Methods | Mathematical Models | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Global Governance | Government/Law | Health/Medicine | Science/Technology | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Dynamic Transmission | State-Transition | Economics/Finance | Child/Nutrition | Health Outcomes | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific